CellaVision AB (publ)

Stockholm Stock Exchange:CEVI.ST

Sector

🏥 Health Care

Industries

💻 Telehealth

🔬 Clinical Trials

💼 Enterprise Resource Planning (ERP)

🩺 Medical Instruments

🌐 Software-as-a-Service (SaaS)

Location

Sweden

Market Cap

USD 453.80 M

Share Price

USD 19.03

Avg Daily Volume

26,505

Change (1 day)

1.31%

Change (1 year)

-18.62%

Change (YTD)

-3.13%

CellaVision AB (publ) Market Capitalization on June 27, 2025: USD 453.80 M

CellaVision AB (publ) Market Capitalization is USD 453.80 M on June 27, 2025, a -18.62% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

CellaVision AB (publ) 52-week low Market Capitalization is USD 684.87 M on June 27, 2025, which is 50.92% above the current Market Capitalization.
CellaVision AB (publ) 52-week low Market Capitalization is USD 354.32 M on June 27, 2025, which is -21.92% below the current Market Capitalization.
CellaVision AB (publ) average Market Capitalization for the last 52 weeks is USD 506.88 M.

Daily

From:

To:

Zoom:

Key data

Date	Market Capitalization	Share Price	Share Price	Price to Earnings Ratio (P/E)

Stockholm Stock Exchange: CEVI.ST

CellaVision AB (publ)

CEO	Mr. Simon Ostergaard Ph.D.
IPO Date	May 28, 2007
Location	Sweden
Headquarters	Mobilvägen 12
Employees	228
Sector	🏥 Health Care
Industries Telehealth 🔬 Clinical Trials 💼 Enterprise Resource Planning (ERP) 🩺 Medical Instruments 🌐 Software-as-a-Service (SaaS)

Description

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.